Literature DB >> 8014483

Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

J M Entenza1, U Fluckiger, M P Glauser, P Moreillon.   

Abstract

The natural history and treatment of experimental endocarditis due to heterogeneous and homogeneous methicillin-resistant Staphylococcus epidermidis was investigated. Amoxicillin/clavulanate or vancomycin were administered for 3 days via a computerized pump to mimic human drug kinetics in animals. After challenge with the minimum inoculum producing 90% of infections (ID90), bacteria in the vegetations grew logarithmically for 16 h. Then, bacterial densities stabilized (at approximately 10(8) cfu/g) and growth rates sharply declined. Both regimens cured > or = 60% of endocarditis (due to heterogeneous or homogeneous bacteria) when started 12-16 h after infection, although the bacterial densities in the vegetations had increased by 20 times in between. In contrast, treatment started after 24 h failed in most animals, while bacterial densities had not increased any more. Thus, while both regimens were equivalent, the therapeutic outcome was best predicted by growth rates in the vegetations, not by bacterial densities. These observations highlight the importance of phenotypic tolerance developing in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014483     DOI: 10.1093/infdis/170.1.100

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.

Authors:  J M Entenza; P Hohl; I Heinze-Krauss; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.

Authors:  Jacques Vouillamoz; José M Entenza; Peter Hohl; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

4.  Handwashing patterns in primary pediatric community clinics.

Authors:  H A Cohen; A Matalon; J Amir; G Paret; A Barzilai
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

5.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.

Authors:  J M Entenza; O Marchetti; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.

Authors:  Juliette Pavie; Agnès Lefort; Virginie Zarrouk; Françoise Chau; Louis Garry; Roland Leclercq; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

8.  RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci.

Authors:  F L'Hériteau; J M Entenza; F Lacassin; C Leport; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

9.  Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.

Authors:  J M Entenza; H Drugeon; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.